Surgical Sealants, Inc. Hoping To Debut SurgiSeal Vascular Sealant In 2000
This article was originally published in The Gray Sheet
Executive Summary
Development stage Surgical Sealants, Inc. is currently conducting clinical trials of its collagen-based SurgiSeal vascular sealant and expects to submit a 510(k) to FDA by year-end.
You may also be interested in...
In Brief: Bio-Vascular
Bio-Vascular: Expects accelerated European sales of its Peri-Strips Dry bovine pericardium-based staple line reinforcements in late 1997, when the company is scheduled to complete multi-center trials evaluating use of the products in lung volume reduction procedures performed on patients suffering from late-stage emphysema. The company commenced U.S. sales of the product, which replaces an earlier version of the Peri-Strips device, in mid-July following FDA clearance in early May...
FUSION MEDICAL TECHNOLOGIES RAPISEAL 510(k) FILED IN APRIL, FIRM SAYS IN PROSPECTUS; 96% EFFECTIVENESS RATE IN LUNG RESECTION PATIENTS SHOWN IN CLINICALS
Fusion Medical Technologies' RapiSeal collagen-based biodegradable patch successfully treated 96% of air leaks in a study of cancer patients who were undergoing lung resection surgery, the Mountain View, California-based firm says in a preliminary prospectus for its initial public offering.
Darzalex Surpasses Stelara As J&J’s Best-Selling Drug
Sales of Stelara are expected to begin tapering off later this year when the first biosimilars launch in mid-2024 in Europe and later in the US.